Table 1.
Baseline characteristics
| Characteristic | HCPro N = 535 |
Non-HCPro N = 24,232 |
P valuea |
|---|---|---|---|
| Age (years), mean ± SD | 48.1 ± 12.2 | 48.4 ± 12.6 | 0.562 |
| Male, n (%) | 170 (31.8) | 8293 (34.2) | 0.238 |
| Household income, n (%) | |||
| $0–$29,999 | 43 (8.0) | 1807 (7.5) | 0.614 |
| $30,000–$49,999 | 56 (10.5) | 2458 (10.1) | 0.806 |
| $50,000–$74,999 | 81 (15.1) | 3771 (15.6) | 0.790 |
| $75,000–$99,999 | 96 (17.9) | 3396 (14.0) | 0.010 |
| > $100,000 | 122 (22.8) | 6384 (26.3) | 0.066 |
| Unknown | 137 (25.6) | 6416 (26.5) | 0.652 |
| Expected patient copay, mean ± SD | $206 ± $678 | $265 ± $1031 | 0.011 |
| $0–$25, n (%) | 320 (59.8) | 13,394 (55.3) | 0.037 |
| $26–$100, n (%) | 110 (20.6) | 6228 (25.7) | 0.007 |
| $101–$500, n (%) | 55 (10.3) | 2244 (9.3) | 0.421 |
| $501–$1000, n (%) | 22 (4.1) | 773 (3.2) | 0.231 |
| $1001–$2000, n (%) | 8 (1.5) | 427 (1.8) | 0.642 |
| > $2000, n (%) | 20 (3.7) | 1166 (4.8) | 0.250 |
| Calendar year, n (%) | |||
| 2012 | 39 (7.3) | 8525 (35.2) | < 0.001 |
| 2013 | 253 (47.3) | 8330 (34.4) | < 0.001 |
| 2014 | 234 (43.7) | 6961 (28.7) | < 0.001 |
| 2015 | 9 (1.7) | 416 (1.7) | 0.952 |
| Primary plan, n (%) | |||
| Commercial | 14 (2.6) | 765 (3.2) | 0.479 |
| Employer group | 43 (8.0) | 2118 (8.7) | 0.569 |
| Third party administrator | 0 (0.0) | 67 (0.3) | 0.223 |
| Pharmacy benefit manager | 139 (26.0) | 6798 (28.1) | 0.291 |
| Cash | 70 (13.1) | 2264 (9.3) | 0.003 |
| Processors | 8 (1.5) | 976 (4.0) | 0.003 |
| Worker’s compensation | 0 (0.0) | 3 (0.0) | 0.797 |
| Unspecified or missing | 261 (48.8) | 11,241 (46.4) | 0.272 |
| PSP enrollment, n (%)b | 378 (70.7) | 12,316 (50.8) | < 0.001 |
| Initial claim at a specialty pharmacy, n (%)c | 351 (65.6) | 13,638 (56.3) | < 0.001 |
| Charlson Comorbidity Index, mean ± SD | 0.54 ± 0.8 | 0.52 ± 0.8 | 0.809 |
| Indications, n (%) | |||
| Rheumatoid arthritis | 319 (59.6) | 13,854 (57.2) | 0.257 |
| Crohn disease | 84 (15.7) | 3477 (14.3) | 0.378 |
| Ulcerative colitis | 51 (9.5) | 1915 (7.9) | 0.168 |
| Psoriasis | 108 (20.2) | 5882 (24.3) | 0.029 |
| Psoriatic arthritis | 97 (18.1) | 4473 (18.5) | 0.847 |
| Ankylosing spondylitis | 25 (4.7) | 1249 (5.2) | 0.618 |
HCPro HUMIRA Complete Pro, PSP patient support program, SD standard deviation
aWilcoxon rank-sum tests and chi-square tests were used to compare continuous and categorical variables, respectively
bDefined as enrollment in any PSP component within 30 days of the index date
cDefined as a pharmacy type of mail order/specialty